HISTORI Experience – a qualitative study of HISTORI patients´ experiences with Semaglutide and placebo

Introduction Qualitative studies of the connection between overweight/ obesity, medicine adherence and symptoms of psychosis are lacking. The project Home-based Intervention with Semaglutide Treatment of Neuroleptica-Related Prediabetes, HISTORI, was a blinded, randomized control trial where people with schizophrenia and prediabetes were randomized to either Semaglutide og placebo injections. Objectives The research question in HISTORI Experience focused on the patients´ mindset while participating in HISTORI, their experiences and thoughts regarding weight and exercise, eating behaviors, psychotic symptoms and their interactions with HISTORI staff. Methods 19 qualitative, semi structured interviews were conducted. 11 Semaglutide interviews (6 female, 5 male) and 9 placebo interviews (5 female, 3 male). The interviews were analyzed with a reflexive thematic analysis (Braun & Clarke, 2022). Patient and Public Involvement: One person with lived experience who could not be included in the HISTORI project, joined HISTORI Experience as a co-researcher. She was involved in creating a phenomenological interview guide. She was then introduced to the coding process and participated in the development of themes. A didactic relationship model was applied as an overall framework for the involvement (Hiim & Hippe, 2007). This model is learning-oriented and takes different factors that might influence the coorporation into account. Factors such as setting, learners´ abilities, learning process, content, goal and evaluation. To ensure a sustainable and active involvement the Involvement Matrix (Smits et al . Research Involvement and Engagement; 2020) was used both prospective and retrospective throughout the involvement process. Results The results from both HISTORI and HISTORI Experience provides us with new knowledge that can be implementet in treatment with Semaglutide for patients with schizophrenia. Conclusions Results and conclusion are expected in April 2025 and will be represented at the EPA conference. Disclosure of Interest None Declared